Why the study?
Do MIB-1 index and tumour size predict metastatic disease in patients with primary synovial sarcoma?
Do MIB-1 index and tumour size predict metastatic disease in patients with primary synovial sarcoma?
MIB-1 index combined with tumor size strongly predicts metastatic risk in synovial sarcoma, helping identify candidates for adjuvant chemotherapy.
Answers are grounded in this paper and cite their sources.
May stratify metastatic risk in synovial sarcoma; extends prognostic factors but leaves open impact on adjuvant decisions.
In a study based on formalin-fixed paraffin-embedded material from 86 patients with primary synovial sarcoma located in the extremities or on the trunk wall, the prognostic importance of MIB-1 index, p53-expession and tumour size was analysed. Multivariate analysis identified two metastatic risk factors: increasing tumour size and MIB-1 > 9%. The 5-year metastasis-free survival-rate for patients with tumour size < or = 5 cm + MIB-1 < 10% was 0.83 (95% confidence interval (CI) 0.64-0.92) compared to 0.31 (95% CI 0.11-0.53) in cases with tumour size > 5 cm + MIB-1 > or = 10%. Our study shows that metastatic disease in synovial sarcoma is closely related to MIB-1 index. Using our model based on tumour size and MIB-1 index, cases with good and poor prognosis can easily be discriminated. Therefore our model can be used to identify patients who should be considered for adjuvant chemotherapy.
No takes yet. Share an insight, caveat, or question.
Skytting et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: